Eli Lilly 将来の成長

Future 基準チェック /56

Eli Lilly利益と収益がそれぞれ年間23%と14.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に60.3% 22.3%なると予測されています。

主要情報

23.0%

収益成長率

22.33%

EPS成長率

Pharmaceuticals 収益成長	14.4%
収益成長率	14.7%
将来の株主資本利益率	60.30%
アナリストカバレッジ	Good
最終更新日	23 Dec 2025

今後の成長に関する最新情報

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

May 05

Recent updates

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Dec 24

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Nov 25

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 07

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Sep 19Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

May 05

業績と収益の成長予測

NYSE:LLY - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	89,458	34,933	25,479	32,481	25
12/31/2026	76,578	28,195	17,478	25,815	29
12/31/2025	63,642	20,399	11,215	19,156	25
9/30/2025	59,420	18,412	7,038	16,062	N/A
6/30/2025	53,258	13,800	551	10,938	N/A
3/31/2025	49,003	11,106	-668	9,318	N/A
12/31/2024	45,043	10,590	1,016	8,818	N/A
9/30/2024	40,863	8,370	-2,275	6,032	N/A
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,469	6,215	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	N/A	4,933	N/A
3/31/2019	21,622	2,545	N/A	5,399	N/A
12/31/2018	21,493	3,151	N/A	5,525	N/A
9/30/2018	22,016	372	N/A	5,819	N/A
6/30/2018	22,368	-166	N/A	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LLYの予測収益成長率 (年間23% ) は貯蓄率 ( 3.3% ) を上回っています。

収益対市場: LLYの収益 ( 23% ) はUS市場 ( 16.2% ) よりも速いペースで成長すると予測されています。

高成長収益: LLYの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: LLYの収益 ( 14.7% ) US市場 ( 10.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: LLYの収益 ( 14.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LLYの自己資本利益率は、3年後には非常に高くなると予測されています ( 60.3 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/12/26 00:21
終値	2025/12/24 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Eli Lilly and Company 29 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。53

アナリスト	機関
David Toung	Argus Research Company
Luisa Hector	Berenberg
Kerry Holford	Berenberg

Eli Lilly 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Eli Lilly and Company Reaffirms Earnings Guidance for the Year 2025

Recent updates

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Dividend of US$1.73 announced

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Now 20% undervalued

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Second quarter dividend of US$1.50 announced

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years

Investor sentiment improves as stock rises 16%

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast Cancer

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of Mounjaro

Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3

Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research Investment

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of Jaypirca

Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung Cancer

Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE Trial

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 Trial

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Chairman recently bought US$1.1m worth of stock

Ken Paxton Files Lawsuit in State Court Against Eli Lilly and Co

Chairman recently bought US$1.1m worth of stock

Chairman recently bought US$1.1m worth of stock

New major risk - Earnings quality

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of US$1.50 per share

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Announces Topline Results from SURPASS-CVOT

Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 Study

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of Jaypirca

Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025

Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease

First quarter dividend of US$1.50 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025

Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

Lilly to Offer All Approve Doses of Zepbound (Tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy Solutions

Eli Lilly Reportedly Nears $1.3 Billion Deal for Verve Therapeutics

Eli Lilly and Company Presents First Clinical Data for Its Investigational, Next-Generation Fra Targeting Adc in Platinum-Resistant Ovarian Cancer At the 2025 Asco Annual Meeting

Eli Lilly and Company (NYSE:LLY) agreed to acquire SiteOne Therapeutics, Inc. for $1 billion.

Eli Lilly and Company Announces Details of Presentation at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Eli Lilly and Company Receives Marketing Authorization in Australia for the Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of Medicine

First quarter dividend of US$1.50 announced

Eli Lilly and Company, Lilly Cardiometabolic Health and Lilly Usa, Llc Announces Executive Appointments